Lara D. Veeken · 2022 · 22 citations · 17 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical CardiologyPulmonary Function TestingCardiac BiomarkersCardiac ImagingCardiac Nuclear ImagingCardiomyopathy PharmacotherapyInterstitial Lung Disease ImagingCardiac Magnetic Resonance BiomarkersExtracellular Volume ImagingMagnetic ResonanceSerum BiomarkersVentricular Ejection Fraction Assessment
OBJECTIVES: Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with SSc. The aim of this study was to explore the effect of nintedanib on cardiomyopathy associated with systemic sclerosis (SSc). METHODS: Twenty consecutively hospitalized patients with SSc-ILD were enrolled and prospectively followed. The rate of change at 6 months in cardiac magnetic resonance (CMR) parametric mapping, including myocardial extracellular volume, was primarily evaluated. Other endpoints included changes in CMR functional parameters, echocardiographic parameters, modified Rodnan skin score, serum biomarkers and pulmonary function test. RESULTS: Nintedanib was administered in 10 patients, whereas the other 10 were treated without nintedanib or watched, according to ILD severity and progression. Baseline values of CMR parametric mapping were not different between the two groups. The rate of change at 6 months in myocardial extracellular volume was highly different, almost divergent, between the nintedanib group and the control group (-1.62% vs +2.00%, P = 0.0001). Among other endpoints, the change in right ventricular ejection fraction was significantly different between the two groups (P = 0.02), with a preferential change in the nintedanib group. CONCLUSION: Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc. The anti-fibrotic effect of nintedanib might not be limited to the lung.
17
F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2013 · 2.9K citations
Daniel Messroghli, James Moon, Vanessa M. Ferreira et al. · Journal of Cardiovascular Magnetic Resonance · 2016 · 1.7K citations · Full text
Medicine, Cardiology, Radiology +17
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.6K citations · Full text
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux et al. · Journal of Pharmacology and Experimental Therapeutics · 2014 · 626 citations